# CRISPR Therapeutics AG > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/CRISPR Therapeutics AG). ## Overview CRISPR Therapeutics AG is a gene-editing biopharmaceutical company built around CRISPR/Cas9 technology and the development of gene-based medicines for serious diseases. Its most important commercial milestone is CASGEVY, the first approved CRISPR-based therapy, which it co-develops and co-commercializes with Vertex Pharmaceuticals for sickle cell disease and transfusion-dependent beta thalassemia. Beyond hemoglobinopathies, the company is building a pipeline across in vivo editing, CAR T approaches, regenerative medicine, and type 1 diabetes. The business is still heavily research- and development-driven, with value creation tied to clinical progress, regulatory approvals, manufacturing execution, and partner-led commercialization. ## Products & services • CASGEVY (exagamglogene autotemcel) for SCD and TDT • In vivo CRISPR-based therapeutic programs • CAR T and engineered cell therapy programs • Regenerative medicine programs • Type 1 diabetes research programs • CRISPR-X next-generation editing platform • Delivery technologies and non-viral editing approaches - **Commercial gene-edited therapy** (45%) — Approved CRISPR-based medicine and related commercialization activities for hemoglobinopathies. - **Clinical-stage in vivo programs** (20%) — Programs that deliver CRISPR-based therapeutics directly into the body for liver and other targets. - **Cell therapy and CAR T programs** (15%) — Engineered cell therapy candidates developed using CRISPR editing and partner collaborations. - **Early-stage research platforms** (10%) — CRISPR-X and other next-generation editing technologies designed to expand the platform. - **Partnership and collaboration revenue** (10%) — Milestones, option fees, and shared development economics from strategic alliances such as Vertex. - CASGEVY (exagamglogene autotemcel) for severe sickle cell disease and TDT - Ex vivo CRISPR/Cas9 gene-edited cell therapy programs - In vivo gene-editing programs for common and rare diseases - CAR T and other engineered cellular therapy programs - Regenerative medicine programs - CRISPR-X next-generation editing modalities - Delivery technologies including non-viral and LNP-based approaches ## Customers The company’s direct commercial customers are patients with severe genetic diseases, but the purchasing and reimbursement process runs through specialty healthcare systems, hospitals, transplant centers, and payers. For CASGEVY, treatment is concentrated in qualified centers that can perform the complex cell collection, conditioning, and infusion workflow required for ex vivo gene editing. In practice, Vertex and CRISPR Therapeutics rely on physicians, treatment centers, and reimbursement authorities to drive adoption, while the company’s pipeline programs are still bought indirectly through clinical trial participation and partner funding. The customer base is therefore a mix of healthcare providers, payers, and strategic partners rather than a broad end-market consumer base. - **Patients with hemoglobinopathies** (primary) — Patients with severe sickle cell disease or transfusion-dependent beta thalassemia who are eligible for CASGEVY through specialized treatment centers. - **Specialty treatment centers and hospitals** (primary) — Centers that perform patient identification, cell collection, conditioning, infusion, and follow-up for approved and clinical-stage cell therapies. - **Payers and public health systems** (primary) — Insurers and government health systems that approve and reimburse expensive one-time gene therapies based on clinical and economic evidence. - **Strategic pharmaceutical partners** (primary) — Partners such as Vertex that co-develop, co-commercialize, manufacture, or fund programs to accelerate development and market access. - **Clinical trial participants** (secondary) — Patients enrolled in early- and mid-stage studies for in vivo, CAR T, regenerative medicine, and diabetes programs. - Specialty treatment centers that administer CASGEVY and manage the cell-therapy workflow - Physicians treating sickle cell disease and transfusion-dependent beta thalassemia - Payers and national health systems that determine reimbursement for high-cost gene therapies - Clinical trial sites that enroll patients in pipeline studies - Strategic partners such as Vertex that fund, develop, and commercialize programs - Research collaborators and biotech partners that license or co-develop platform technologies ## Geography The company is headquartered in the United States but operates as a global gene-therapy developer with clinical, regulatory, and commercial exposure across the U.S., Europe, and other major markets. CASGEVY has been approved in the United States and other countries, so commercialization depends on country-by-country reimbursement and treatment-center readiness. The reports also highlight increasing genetic-medicine competition in China, which makes Asia an important strategic and competitive reference point even if the company’s own revenue disclosure is not broken out by country. Because manufacturing and treatment delivery for cell therapies are complex, geography matters not only for market access but also for regulatory approvals, supply chain coordination, and partner execution. - Headquartered in the United States, with U.S. commercialization and clinical development as a core base - CASGEVY is approved in the United States and other countries, creating multi-market launch exposure - Europe is important because gene-therapy regulation and reimbursement differ by country - China is a competitive hotspot for genetic medicine development and a source of emerging rivals - Global treatment-center expansion matters because cell therapies require specialized infrastructure - Manufacturing and supply-chain execution are critical across jurisdictions for patient access ## Strategy The company’s strategy is to convert CRISPR/Cas9 from a platform into a portfolio of approved and clinically differentiated medicines across multiple disease areas. Near term, the priority is to expand the commercial and clinical footprint of CASGEVY while supporting Vertex-led commercialization and manufacturing execution. Medium term, management is pushing in vivo editing, CRISPR-X next-generation modalities, and delivery technologies such as non-viral systems and LNPs to broaden the addressable patient population beyond ex vivo cell therapy. The company is also using partnerships to share development risk, access disease-area expertise, and accelerate programs in hemoglobinopathies, DMD, DM1, diabetes, and other therapeutic areas. - **Commercialize and expand CASGEVY** (short-term) — The approved product is the clearest path to near-term value creation and validates the platform. - **Advance in vivo editing programs** (medium-term) — In vivo delivery could open larger markets than ex vivo cell therapy and reduce treatment complexity. - **Build next-generation editing and delivery platforms** (medium-term) — New editing chemistries and delivery methods are needed to stay competitive as the field evolves. - **Leverage partnerships to broaden the pipeline** (short-term) — Collaborations reduce capital intensity and provide access to disease expertise and commercialization capabilities. - Expand adoption of CASGEVY through treatment-center and reimbursement execution - Advance in vivo editing programs to reach diseases not suited to ex vivo therapy - Develop CRISPR-X next-generation editing tools for whole-gene correction and insertion - Improve delivery technologies, including non-viral and LNP-based approaches - Use partnerships to share cost, reduce risk, and accelerate clinical development - Broaden the pipeline across hemoglobinopathies, CAR T, regenerative medicine, and T1D ## Risks The company faces substantial clinical, regulatory, and manufacturing risk because its business depends on proving that highly complex gene-editing therapies are safe, effective, and scalable. CASGEVY’s commercialization is also exposed to partner dependence, since Vertex has significant control over the program and is the manufacturer and exclusive license holder. Competition is intense and technologically fluid, with rival approaches including base editing, RNA editing, TALENs, and traditional gene therapy potentially displacing CRISPR/Cas9 in some indications. Broader industry risks include changing FDA, EMA, and MHRA expectations, supply-chain or lot-failure issues, and the possibility that reimbursement or market access for high-cost therapies develops more slowly than expected. - **Clinical development failure or delay** [high] — The pipeline depends on successful preclinical and clinical outcomes, and setbacks can stop or postpone commercialization. - **Manufacturing quality and supply-chain disruption** [high] — Cell and gene therapies require tightly controlled manufacturing; deviations can cause lot failures, recalls, and trial delays. - **Partner dependence on Vertex** [high] — Vertex is the manufacturer and exclusive license holder of CASGEVY and has significant control over the program. - **Competitive displacement by alternative editing technologies** [medium] — Base editing, RNA editing, TALENs, and other platforms may prove more attractive in certain indications. - **Regulatory tightening for gene therapy** [medium] — FDA, EMA, and MHRA scrutiny can delay or prevent approvals and increase development burden. - Clinical failure or delays could prevent product approval or reduce the value of the pipeline - Manufacturing deviations can cause lot failures, recalls, and supply interruptions - Vertex controls key aspects of CASGEVY, creating partner concentration and execution risk - Gene-editing competition is intense and may shift toward alternative technologies - Regulatory scrutiny of gene therapy and genetic testing can slow approvals and commercialization - Reimbursement and treatment-center adoption may limit uptake of expensive one-time therapies - Hiring and retaining specialized scientific and manufacturing talent is critical and difficult ## Accounting Revenue recognition is a key judgment area because the company’s revenue is driven largely by collaboration and license arrangements rather than product sales, and the timing of milestone, option, and development-related payments can be complex under ASC 606. The company states that it has not generated revenue to date from sales of wholly owned products and that revenue can be immaterial or fluctuate significantly from quarter to quarter, which makes period comparisons noisy. Because CASGEVY is co-developed and co-commercialized with Vertex, the accounting for collaboration economics, cost sharing, and any contingent consideration can materially affect reported revenue and operating results. Investors should also watch estimates tied to R&D accruals, clinical trial obligations, and any fair-value or impairment judgments related to long-duration development assets and marketable securities. - **ASC 606 collaboration revenue** — Can cause significant quarterly volatility in reported revenue - **R&D accrual estimates** — Affects operating expenses and loss volatility - **Co-development economics with Vertex** — Can materially affect revenue mix and margin interpretation - **Fair value of marketable securities** — Affects other income and liquidity presentation - Collaboration and license revenue timing under ASC 606 can create lumpy quarterly results - Milestones and option-related payments may be recognized differently from product sales - No meaningful wholly owned product sales means revenue is still highly dependent on partner arrangements - R&D accruals and clinical trial estimates affect expense recognition and period comparability - Co-development and co-commercialization economics with Vertex can affect revenue classification - Marketable securities and other investments may introduce fair-value and impairment considerations --- *Last updated: 2026-08-11T04:46:27.156558+00:00*